<div id="readability-page-1"><p>Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL - Get Free Report)'s stock price fell 11.7% on Wednesday . The stock traded as low as $7.20 and last traded at $13.8410. 967,940 shares were traded  during mid-day trading, an increase of 62% from the average session volume of 596,093 shares. The stock had previously closed at $15.68.</p><h2>Analyst Upgrades and Downgrades</h2><p>Several brokerages recently weighed in on ANL. Weiss Ratings  reiterated a &#34;sell (e+)&#34; rating on shares of Adlai Nortye in a research report on Wednesday, January 21st. HC Wainwright upgraded shares of Adlai Nortye from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and set a $16.00 price objective on the stock in a research report on Friday, February 13th. Leerink Partners began coverage on shares of Adlai Nortye in a research report on Friday, March 20th. They issued an &#34;outperform&#34; rating and a $23.00 price objective on the stock. Finally, Wall Street Zen upgraded shares of Adlai Nortye to a &#34;hold&#34; rating in a research report on Saturday, March 7th. Two research analysts have rated the stock with a Buy rating and one  has given a Sell rating to the stock. According to MarketBeat.com, Adlai Nortye currently has a consensus rating of &#34;Hold&#34; and an average price target of $19.50.</p><p><b>View Our Latest Research Report on Adlai Nortye</b></p><h2>Adlai Nortye Price Performance</h2><p>The firm's 50-day simple moving average is $9.03 and its 200 day simple moving average is $4.44. </p><h2>About Adlai Nortye</h2> (Get Free Report)<p>Adlai Nortye Inc <span>NASDAQ: ANL<span></span></span> is a specialty chemical manufacturer headquartered in China’s Jiangsu Province. The company focuses on the research, development, production and sale of fine chemicals, with a primary emphasis on amino acids and their derivatives. </p><p>Adlai Nortye’s product portfolio includes betaine compounds, a range of high-purity L-amino acids such as L-methionine, L-threonine and glycine, as well as various chemical intermediates. These offerings serve multiple end markets, including animal feed and nutrition, personal care and cosmetic formulations, pharmaceutical ingredients and industrial chemical processes. </p><p>The company operates multiple production facilities alongside an in-house research and development center dedicated to process innovation and quality control.</p><h2>Read More</h2><ul><li>Five stocks we like better than Adlai Nortye</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Adlai Nortye Right Now?</h2><p>Before you consider Adlai Nortye, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adlai Nortye wasn't on the list.</p><p>While Adlai Nortye currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

SBIO

ARKG

<p>Adlai Nortye (NASDAQ:ANL) saw its stock price drop by 11.7% to $13.84, with trading volume increasing by 62% to 967,940 shares. Analysts have mixed opinions: Weiss Ratings maintains a 'sell' rating, while HC Wainwright upgraded it to 'buy' with a $16 target. Leerink Partners rated it 'outperform' with a $23 target. Currently, the consensus rating is 'Hold' with an average price target of $19.50. Adlai Nortye specializes in fine chemicals, particularly amino acids and derivatives, serving various markets including animal feed and pharmaceuticals.</p>

Adlai Nortye (NASDAQ:ANL) Trading Down 11.7% - Here's What Happened